NiteCAPP: Web-based Interventions for Insomnia in Rural Dementia Caregivers

Sponsor
University of Missouri-Columbia (Other)
Overall Status
Recruiting
CT.gov ID
NCT04896775
Collaborator
(none)
100
1
2
49.9
2

Study Details

Study Description

Brief Summary

Compared to their urban counterparts, rural family dementia caregivers (CGs) face increased vulnerability to insomnia and related health concerns (stress, inflammation, depression, anxiety, cognitive disturbance). Cognitive and behavioral treatments for insomnia hold promise for improving insomnia and these related concerns, but is difficult to access in rural areas. Our team developed brief behavioral sleep intervention that improved sleep, arousal, mood, cognition and inflammation (small to large effects). While telehealth improves accessibility, it is still burdensome for CGs due to inflexible scheduling and scarcity of trained therapists. Thus, more research is needed. Web delivery would increase access and web treatments for insomnia are efficacious in non-CG adults, but has not been tested in rural CGs. The proposed trial tests the novel hypothesis that web-based treatment (NiteCAPP) will improve CG health, mood, burden and cognition by targeting their shared underlying mechanisms

  • sleep, arousal and inflammation - thereby, returning sympathetic and hypothalamic-pituitary-adrenal axis (HPA) functioning to normal. Demonstration that rural CGs can use NiteCAPP to target sleep, arousal/stress, inflammation and related health concerns has important implications for multiple stakeholders, including rural CGs, rural persons with dementia (PWD), their families, clinicians and policymakers.
Condition or Disease Intervention/Treatment Phase
  • Behavioral: NiteCAPP CARES
  • Behavioral: NiteCAPP SHARES
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
NiteCAPP: Web-based Interventions for Insomnia in Rural Dementia Caregivers: Examination of Sleep, Arousal, Mood, Cognitive, and Immune Outcomes
Actual Study Start Date :
Feb 2, 2022
Anticipated Primary Completion Date :
Mar 31, 2026
Anticipated Study Completion Date :
Mar 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: NiteCAPP CARES

Cognitive Behavioral Treatment-Insomnia. 4 online treatment sessions focusing on behavior and cognitions related to sleep.

Behavioral: NiteCAPP CARES
4 session Web-based Cognitive Behavioral Therapy for Insomnia. Individualized sessions moderated by therapist.
Other Names:
  • Web CBT-I
  • Experimental: NiteCAPP SHARES

    Sleep Hygiene and Related Education. 4 online treatment sessions focusing on sleep hygiene and related education.

    Behavioral: NiteCAPP SHARES
    4 session Web-based Sleep Hygiene and Related Education. Individualized sessions moderated by therapist.
    Other Names:
  • Web Sleep Hygiene and Related Education (Web-SHARE)
  • Outcome Measures

    Primary Outcome Measures

    1. Change in Insomnia Severity Index [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Insomnia severity; score range 0-28 (low severity - high severity)

    2. Change in Pain Intensity - Daily Electronic Sleep Diaries [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      Daily electronic dairies will record pain intensity; range: 0-100 (no pain- most intense)

    3. Change in Pain Unpleasantness - Daily Electronic Sleep Diaries [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      Daily electronic dairies will record pain unpleasantness; range: 0-100 (none- most unpleasantness)

    4. Change in Wake After Sleep Onset - Daily Electronic Sleep Diaries [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      Daily electronic dairies will record wake after sleep onset (number of minutes)

    5. Change in Sleep Onset Latency- Daily Electronic Sleep Diaries [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      Daily electronic dairies will record sleep onset latency (number of minutes)

    6. Change in Sleep Efficiency- Daily Electronic Sleep Diaries [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      Daily electronic dairies will record sleep efficiency

    7. Change in Fatigue - Daily Electronic Sleep Diaries [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      Daily electronic dairies will record insomnia severity; range: 0-100 (no insomnia - most severe)

    8. Change in Sleep and Pain Medication - Daily Electronic Sleep Diaries [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      Daily electronic dairies will record daily medication consumption

    9. Change in Perceived Stress Scale [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Perception of stress; score range: 0-40 (low stress - high stress)

    10. Change in Kingston Caregiver Stress Scale (KCSS) [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Caregiver stress level; score range: 10-50 (low caregiver stress - high caregiver stress)

    11. Change in Dysfunctional Beliefs About Sleep (DBAS) [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Sleep-related beliefs; score range: 0-110 (low dysfunctional beliefs - high dysfunctional beliefs)

    12. Change in Peripheral Arousal [5 mins at rest at baseline, 8 weeks, 6 month and 12 follow up]

      Heart Rate Variability (as measured by Holter-Monitoring)

    13. Change in Blood-based Biomarker High Sensitivity C-Reactive Protein (HS-CRP) [Single blood draw at baseline, 8 weeks, 6 month and 12 follow up]

      Inflammation

    14. Change in Blood-based Biomarker Interleukin 6 IL-6) [Single blood draw at baseline, 8 weeks, 6 month and 12 follow up]

      Inflammation

    15. Change in Blood-based Biomarker AβB42 [Single blood draw at baseline, 8 weeks, 6 month and 12 follow up]

      Neurodegenerative

    16. Change in Blood-based Biomarker Tau [Single blood draw at baseline, 8 weeks, 6 month and 12 follow up]

      Neurodegenerative

    Secondary Outcome Measures

    1. Internet Intervention Utility Questionnaire (IIUQ) [Single administration at post-treatment - 8 weeks]

      Modified for NiteCAPP; score range: 0-65 (least satisfied - most satisfied)

    2. Change in State-Trait Anxiety Inventory (STAI) [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Trait and state anxiety; score range: 20-80 (low anxiety - high anxiety)

    3. Change in Depression (Beck Depression Inventory-II) [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Depression severity; score range: 0-63 (normal - extreme depression)

    4. Change in 36-Item Short Form Survey (SF-36) [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Self-reported health; score range: low quality of life to high quality of life

    5. Change in Caregiver Burden (Zarit Burden Scale) [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Caregiver burden; score range: 0-48 (low burden - high burden)

    6. Change in Cognitive Failures Questionnaire (CFQ) [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Frequency of lapses of attention, memory, and cognition in everyday life; score range: 0-100 (low frequency of mistakes - high frequency of mistakes)

    7. Change in Dementia Patient's Caregiver Quality of Life Scale [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Quality of life related to psychological well-being

    8. Change in Objective Wake After Sleep Onset (Actigraph) [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      Wake after sleep onset via Actiwatch-2

    9. Change in Objective Sleep Onset Latency (Actigraph) [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      Sleep Onset Latency via Actiwatch-2

    10. Change in Objective Sleep Efficiently (Actigraph) [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      Sleep Efficiency via Actiwatch-2

    11. Change in NIH Toolbox [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      20 minute computerized cognitive tasks

    12. Change in Daily Joggle Battery [Daily at baseline, 8 weeks, 6 month and 12 follow up]

      15 minute computerized cognitive tasks

    Other Outcome Measures

    1. Change in Neuropsychiatric Inventory(NPI) Nighttime Behavior Scale [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Frequency and severity of the nighttime behavior disturbance; score range: 2-12 (low disturbance - high disturbance)

    2. Change in Dementia Severity Rating Scale [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Dementia severity: score range: 0-54 (mild - moderate)

    3. Change in Patient-Caregiver Functional Unit Scale (PCFUS) [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Stability of the patient-caregiver dyad

    4. Change in Godin Leisure-Time Exercise Questionnaire [Single administration at baseline, 8 weeks, 6 month and 12 follow up]

      Leisure-time physical activities

    5. Satisfaction Survey [Single administration at post-treatment - 8 weeks]

      Experience with the assessments, procedures, and other features of the research study; score range: 9-90 (low satisfaction - high satisfaction)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion:

    Caregiver Eligibility. Inclusion criteria: 1. 18+ yrs, 2. CG living with PWD, 3. willing to be randomized, 4. read/understand English, 5. insomnia diagnosis, 6. no prescribed or over the counter sleep meds for 1+ mo, or stabilized 6+ mos.

    • Insomnia: 1. complaints for 6+ mos, 2. adequate opportunity and circumstances for sleep, 3. 1+ of the following: difficulty falling asleep, staying asleep or waking too early, 4. daytime dysfunction (mood, cognitive, social, occupational) due to insomnia,
    1. baseline diaries indicate >30 mins of sleep onset latency or wake after sleep onset on 3+ nts.

    PWD Eligibility. 1. probable/possible Alzheimer's Disease (self-report or primary care provider written confirm), 2. 1+ problem on Nighttime Behavior Inv. 3+ nts/wk, 3. tolerate actigraphy, 4. no sleep meds 1+ mo or stabilized 6+ mos, 5. untreated sleep disorder for which CBT-I is not recommended (e.g., apnea), 6. scoring <32 on Sleep Apnea scale, Sleep Disorders Ques.

    Exclusion:

    CG Exclusion criteria: 1. unable to consent, 2. cognitive impairment [Telephone Interview for Cognitive Status (TICS) <25], 3. sleep disorder other than insomnia [i.e., apnea (apnea/hypopnea index-AHI >15)], 4. bipolar or seizure disorder, 5. other major psychopathology except depression or anxiety (e.g., suicidal, psychotic), 6. severe untreated psychiatric comorbidity, 7. psychotropic or other medications (e.g., beta-blockers) that alter sleep, 8. non-pharmacological tx for sleep or mood outside current trial.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Missouri Columbia Missouri United States 65212

    Sponsors and Collaborators

    • University of Missouri-Columbia

    Investigators

    • Principal Investigator: Christina S McCrae, University of Missouri-Columbia

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Christina McCrae, Professor, University of Missouri-Columbia
    ClinicalTrials.gov Identifier:
    NCT04896775
    Other Study ID Numbers:
    • 2053682
    First Posted:
    May 21, 2021
    Last Update Posted:
    Mar 2, 2022
    Last Verified:
    Feb 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Christina McCrae, Professor, University of Missouri-Columbia
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 2, 2022